薄层液基细胞学与高危型人乳头瘤病毒DNA检测及阴道镜联合检查在宫颈病变中的临床应用

目的探讨宫颈病变的筛查方法及其临床价值。方法对540例TCT异常患者行HC-(IIHybird Capture-II)高危型HPV-DNA检测,其中120例细胞学结果为ASC的患者因高危型HPV-DNA检测结果阴性未进行阴道镜检查,余均行阴道镜检查及多点活检组织病理学检查。结果液基细胞学与HPV-DNA检测结果比较,ASCUS、LSIL、HISL阳性率分别为36%、53.3%、61.3%,P<0.05;HPV-DNA检测结果与病理结果比较,炎症、CINI、CINII-III阳性率分别为67.2%、68.2%、91.9%,P<0.05,有显著性差异。结论 TCT是宫颈病变筛查中是首选方法,联合高危型HPV-DNA检测及阴道镜检查则能提高宫颈病变的检出率。

Objective The clinical value of cytology high-risk human papillomavirus （HR-HPV） testing and colposcope in diagnosis of precancerous diseases. Methods 540 women with abnormal cervical smear were screened by using HPV DNA testing hybrid capture Ⅱ（HC-Ⅱ）,Among those cases 120 women with high-risk human papillomavirus （HR-HPV） testing negatively cervical smear ASC,were not received Colposcopy. Simultaneously the rest cases were received by colposcopy and colposcope directed biopsy. Results Among 420 cases the positive rates of HR-HPV as ASCUS,LSIL and HSIL were 36%,53.3%,61.3%respectively （P〈0.05）. the positive rates of HR-HPV as inflammation ,CINI and CINII-III were 67.2%,68.2%,91.9% （P〈0.05） ,which have significant deviation.Conclusion Cytology is the preferred method for screening cervical precancerous diseases. Cytology combined with HR-HPV testing and colposcopy can increase the detectable rate of cervical cancer.